Japanese government will purchase 1.6 million courses of the oral COVID-19 drug Molnupiravir from Merck and Ridgeback Biotherapeutics, subject to approval from the Japanese Pharmaceutical and Medical Device Agency. The cost of the batch will be about $1.2 billion.